Moderna
MRNA
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
MarketBeat • 3 days ago • MRNA
The S&P 500's 3 Best-Performing Stocks so far in 2026
Zacks Investment Research • 5 days ago • MRNA
Moderna (MRNA) Declines More Than Market: Some Information for Investors
Seeking Alpha • 9 days ago • MRNA
Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Investors Business Daily • 12 days ago • MRNA
Moderna Pops As Vinay Prasad, The FDA's Controversial Vaccine Head, Will Depart In April
CNBC • 13 days ago • MRNA
FDA reversals leave investors worrying about the fates of other experimental drugs
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.